{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:37:47Z","timestamp":1792172267483,"version":"4.4.0"},"reference-count":91,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or muscle invasive). Patients with muscle-invasive disease will be offered a radical treatment combined with systemic therapy, while in those with non-muscle-invasive disease, an attempt to resect the tumor endoscopically will usually be followed by different intravesical instillations. The goal of intravesical therapy is to decrease the recurrence and\/or progression of the tumor. In the current landscape of bladder cancer treatment, BCG is given intravesically to induce an inflammatory response and recruit immune cells to attack the malignant cells and induce immune memory. While the response to BCG treatment has changed the course of bladder cancer management and spared many \u201cbladders\u201d, some patients may develop BCG-unresponsive disease, leaving radical surgery as the best choice of curative treatment. As a result, a lot of effort has been put into identifying novel therapies like systemic pembrolizumab and Nadofaragene-Firadenovac to continue sparing bladders if BCG is ineffective. Moreover, recent logistic issues with BCG production caused a worldwide BCG shortage, re-sparking interest in alternative BCG treatments including mitomycin C, sequential gemcitabine with docetaxel, and others. This review encompasses both the historic and current role of BCG in the treatment of non-muscle-invasive bladder cancer, revisiting BCG alternative therapies and reviewing the novel therapeutics that were approved for the BCG-unresponsive stage or are under active investigation.<\/jats:p>","DOI":"10.3390\/curroncol31020079","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T03:37:27Z","timestamp":1708054647000},"page":"1063-1078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer"],"prefix":"10.3390","volume":"31","author":[{"given":"Sarah","family":"Lidagoster","sequence":"first","affiliation":[{"name":"Department of Urology, Ichan School of Medicine at the Mount Sinai Hospital, New York, NY 10029, USA"},{"name":"CUNY School of Medicine, City College of New York, New York, NY 10031, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7145","authenticated-orcid":false,"given":"Reuben","family":"Ben-David","sequence":"additional","affiliation":[{"name":"Department of Urology, Ichan School of Medicine at the Mount Sinai Hospital, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"De Leon","sequence":"additional","affiliation":[{"name":"Department of Urology, Ichan School of Medicine at the Mount Sinai Hospital, New York, NY 10029, USA"},{"name":"SUNY Downstate Health Science University, New York, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[{"name":"Department of Urology, Ichan School of Medicine at the Mount Sinai Hospital, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","article-title":"Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis","volume":"30","author":"Borkowski","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s11255-023-03638-6","article-title":"Bladder perforation as a complication of transurethral resection of bladder tumors: The predictors, management, and its impact in a series of 1570 at a tertiary urology institute","volume":"55","author":"Osman","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.euo.2022.05.001","article-title":"En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial","volume":"5","author":"Gallioli","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.euf.2020.08.007","article-title":"Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival","volume":"7","author":"Mastroianni","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756287211431976","article-title":"Best practice in the treatment of nonmuscle invasive bladder cancer","volume":"4","author":"Anastasiadis","year":"2012","journal-title":"Ther. Adv. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa\u2013pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_8","first-page":"43","article-title":"Non-Muscle-invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative Therapies","volume":"22","author":"Matulewicz","year":"2020","journal-title":"Rev. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11934-012-0234-4","article-title":"Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer","volume":"13","author":"Collado","year":"2012","journal-title":"Curr. Urol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0022-5347(17)53283-8","article-title":"Bladder cancer immunotherapy","volume":"128","author":"Lamm","year":"1982","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MOU.0000000000000595","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) treatment of bladder cancer: A systematic review and commentary on recent publications","volume":"29","author":"Mukherjee","year":"2019","journal-title":"Curr. Opin. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.170.3963.1217","article-title":"Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG)","volume":"170","author":"Zbar","year":"1970","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.juro.2016.10.101","article-title":"Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors","volume":"197","author":"Morales","year":"2017","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) Therapy for Bladder Cancer: An Update","volume":"9","year":"2020","journal-title":"Immunotargets Ther."},{"key":"ref_15","first-page":"65","article-title":"Immunotherapy for bladder cancer","volume":"7","author":"Fuge","year":"2015","journal-title":"Res. Rep. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","article-title":"Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Audisio, A., Buttigliero, C., Delcuratolo, M.D., Parlagreco, E., Audisio, M., Ungaro, A., Di Stefano, R.F., Di Prima, L., Turco, F., and Tucci, M. (2022). New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. Cells, 11.","DOI":"10.3390\/cells11030357"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: Results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How to Manage Them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.jctube.2020.100149","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) treatment\u2019s severe complications: A single institution review of incidence, presentation and treatment outcome","volume":"19","author":"Waked","year":"2020","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0022-5347(17)41803-9","article-title":"Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer","volume":"140","author":"Oates","year":"1988","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/RCT.0b013e3182aac58a","article-title":"Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical Bacillus Calmette-Guerin therapy","volume":"38","author":"Logan","year":"2014","journal-title":"J. Comput. Assist. Tomogr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1442-2042.2006.01257.x","article-title":"Epididymo-orchitis caused by intravesically instillated bacillus Calmette-Gu\u00e9rin: Genetically proven using a multiplex polymerase chain reaction method","volume":"13","author":"Harada","year":"2006","journal-title":"Int. J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejvsvf.2023.02.003","article-title":"BCG Aortitis, a Rare Complication of BCG Therapy","volume":"58","author":"Haddad","year":"2023","journal-title":"EJVES Vasc. Forum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e243641","DOI":"10.1136\/bcr-2021-243641","article-title":"Systemic infection following intravesical therapy with BCG","volume":"14","author":"Oliveira","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_26","unstructured":"(2023, November 21). Non-Muscle-Invasive Bladder Cancer\u2014DISEASE MANAGEMENT\u2014Uroweb. Available online: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer\/chapter\/disease-management."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00345-021-03666-w","article-title":"BCG-unresponsive high-grade non-muscle invasive bladder cancer: What does the practicing urologist need to know?","volume":"39","author":"Lebacle","year":"2021","journal-title":"World J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-Risk Non-Muscle-Invasive Bladder Cancer\u2014Therapy Options During Intravesical BCG Shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr. Urol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-\u03b1 2B Enhances Th1 Cytokine Responses in Bladder Cancer Patients Receiving Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin Immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bju.13211","article-title":"The effectiveness of BCG and interferon against non-muscle invasive bladder cancer: A New Zealand perspective","volume":"116","author":"Tatton","year":"2015","journal-title":"BJU Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"Krohn","year":"2001","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3810\/hp.2013.10.1078","article-title":"Salvage combination intravesical immunotherapy with Bacillus Calmette-Gu\u00e9rin and interferon-\u03b12B: Impact on recurrence, progression, and survival","volume":"41","author":"Prasad","year":"2013","journal-title":"Hosp. Pract."},{"key":"ref_34","first-page":"CD012112","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin with interferon-alpha versus intravesical Bacillus Calmette-Gu\u00e9rin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115315","DOI":"10.18632\/oncotarget.23258","article-title":"Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: An EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Gu\u00e9rin Unresponsive or Recurrent\/Relapsing Urothelial Carcinoma of the Bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J. Urol."},{"key":"ref_38","first-page":"123","article-title":"Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial","volume":"20","author":"Djafari","year":"2023","journal-title":"Urol. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4111\/icu.20210265","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review","volume":"62","author":"Han","year":"2021","journal-title":"Investig. Clin. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): A systematic review","volume":"109","author":"Shelley","year":"2012","journal-title":"BJU Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.mou.0000240310.70582.ce","article-title":"Intravesical gemcitabine: An update of clinical results","volume":"16","author":"Hendricksen","year":"2006","journal-title":"Curr. Opin. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.urology.2021.04.062","article-title":"Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer","volume":"156","author":"Kuperus","year":"2021","journal-title":"Urology"},{"key":"ref_44","unstructured":"(2023, November 21). Study Details|A Study of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Gu\u00e9rin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04640623."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.euf.2021.07.018","article-title":"Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro","volume":"8","author":"Black","year":"2022","journal-title":"Eur. Urol. Focus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Gu\u00e9rin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Gu\u00e9rin-Na\u00efve High-Risk Nonmuscle-Invasive Bladder Cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e230849","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Gu\u00e9rin for the Treatment of Patients with High-Risk Non\u2013Muscle-Invasive Bladder Cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_49","first-page":"458.e1","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_50","unstructured":"(2023, December 02). A Randomized Phase III Trial of Intravesical BCG versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naive Non-Muscle Invasive Bladder Cancer (The BRIDGE Trial)\u2014NCI, Available online: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2022-04864&r=1."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/1074-5521(95)90120-5","article-title":"Mitomycin C: Small, fast and deadly (but very selective)","volume":"2","author":"Tomasz","year":"1995","journal-title":"Chem. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.survophthal.2009.04.002","article-title":"Mitomycin C in corneal refractive surgery","volume":"54","author":"Teus","year":"2009","journal-title":"Surv. Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/ctrv.2000.0202","article-title":"Mitomycin C: A clinical update","volume":"27","author":"Bradner","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.2910510305","article-title":"Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times","volume":"51","author":"Sleeboom","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1586\/14737140.6.8.1273","article-title":"Intravesical mitomycin C for superficial transitional cell carcinoma","volume":"6","author":"Bolenz","year":"2006","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00345-018-2591-1","article-title":"Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: How, when and what","volume":"37","author":"Peyton","year":"2019","journal-title":"World J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","article-title":"Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: A subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up","volume":"56","author":"Kaasinen","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.eururo.2004.05.003","article-title":"One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?","volume":"46","author":"Oddens","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J. Urol."},{"key":"ref_60","first-page":"CD011935","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol."},{"key":"ref_62","unstructured":"Dalton, J.T., Wientjes, M.G., Badalament, R.A., Drago, J.R., and Au, J.L. (2023, November 25). Pharmacokinetics of Intravesical Mitomycin C in Superficial Bladder Cancer Patients. Available online: http:\/\/aacrjournals.org\/cancerres\/article-pdf\/51\/19\/5144\/2444855\/cr0510195144.pdf."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1464-410x.2000.00539.x","article-title":"Perivesical inflammation after early mitomycin C instillation","volume":"85","author":"Cliff","year":"2000","journal-title":"BJU Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1111\/bju.12340","article-title":"Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)\u2014Avoidance, recognition, management and consent","volume":"113","author":"Elmamoun","year":"2014","journal-title":"BJU Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","article-title":"Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Gu\u00e9rin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Gu\u00e9rin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial","volume":"75","author":"Tan","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/02656736.2016.1141239","article-title":"Overview of bladder heating technology: Matching capabilities with clinical requirements","volume":"32","author":"Stauffer","year":"2016","journal-title":"Int. J. Hyperth."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1038\/s41598-022-11016-y","article-title":"A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer","volume":"12","author":"Scutigliani","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/14737140.2016.1126515","article-title":"The role of hyperthermia as a treatment for non-muscle invasive bladder cancer","volume":"16","author":"Bahouth","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Plata, A., Guerrero-Ramos, F., Garcia, C., Gonz\u00e1lez-D\u00edaz, A., Gonzalez-Valc\u00e1rcel, I., de la Morena, J.M., D\u00edaz-Goizueta, F.J., del \u00c1lamo, J.F., Gonzalo, V., and Montero, J. (2021). Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. J. Clin. Med., 10.","DOI":"10.3390\/jcm10215105"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0022-5347(01)63728-5","article-title":"Local Microwave Hyperthermia and Intravesical Chemotherapy as Bladder Sparing Treatment for Select Multifocal and Unresectable Superficial Bladder Tumors","volume":"159","author":"Colombo","year":"1998","journal-title":"J. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/21681805.2021.1938664","article-title":"Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients","volume":"55","author":"Thomsen","year":"2021","journal-title":"Scand. J. Urol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","article-title":"Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma","volume":"52","author":"Paroni","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"76.e9","DOI":"10.1016\/j.urolonc.2020.07.003","article-title":"Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia","volume":"39","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"LBA442","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA442","article-title":"Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette\u2013Gu\u00e9rin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial","volume":"41","author":"Necchi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1040669","DOI":"10.3389\/fimmu.2022.1040669","article-title":"ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e1047","DOI":"10.1097\/JU.0000000000002671.01","article-title":"PLLBA-01 FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15R\u0391FC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS","volume":"207","author":"Chang","year":"2022","journal-title":"J. Urol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","article-title":"Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)","volume":"40","author":"Chamie","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"35.e21","DOI":"10.1016\/j.urolonc.2013.02.010","article-title":"Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer","volume":"32","author":"Lamm","year":"2014","journal-title":"Urol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-1-0716-3291-8_19","article-title":"Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer","volume":"2684","author":"Grandi","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_84","first-page":"103","article-title":"Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy","volume":"10","author":"Morizawa","year":"2018","journal-title":"Res. Rep. Urol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Deininger, S., T\u00f6rzs\u00f6k, P., Mitterberger, M., Pallauf, M., Oswald, D., Deininger, C., and Lusuardi, L. (2022). From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Gu\u00e9rin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC). Cancers, 14.","DOI":"10.3390\/cancers14030694"},{"key":"ref_87","first-page":"440","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non\u2013muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","article-title":"CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer","volume":"25","author":"Chang","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2023.04.013","article-title":"Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes","volume":"53","author":"Tan","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"TPS4620","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4620","article-title":"Phase 1a\/b safety study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer (ADVANCED-1)","volume":"40","author":"Bandari","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/2\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:00:24Z","timestamp":1760104824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/2\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["curroncol31020079"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31020079","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}